For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- HIV Combo Pill Prezcobix OK’ed for NHI Price Listing
December 1, 2016
- Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
- Chuikyo at Odds over Price Maintenance Premium
December 1, 2016
- Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
- “Outright” or “Partial”? Annual Revision Debate Rekindled in a Rush to Revamp Drug Pricing
November 30, 2016
- MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
November 30, 2016
- Shiozaki Hints at Possible Drug Price Survey in Different Method
November 30, 2016
- Before Micatrio, Patient Must Take 3 Contained Compounds for at Least 8 Weeks: MHLW
November 29, 2016
- Japan Ophthalmologists Association Calls for Reductions in NHI Prices of High-Cost Drugs
November 29, 2016
- LDP Study Group Kicks Off to Put Brakes on Hasty Push for Biosimilars
November 28, 2016
- Eltrombopag, Nusinersen Designated as Orphan Drugs
November 28, 2016
- MHLW Advisory Panel OKs Biogen’s Tecfidera, Other Drugs
November 28, 2016
- Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
November 28, 2016
- MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
November 25, 2016
- MHLW Looks to Extend MID-NET to Cover Clinic Data: Bureau Chief
November 25, 2016
- More Patient Participation Needed to Promote Drug Development, Safety Measures: MHLW Official
November 25, 2016
- Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016
- Polaprezinc Ordered to Add Copper Deficiency in ADR List
November 24, 2016
- LDP’s Health Committee Demands Enhanced R&D Tax Break as Key Priority
November 24, 2016
- MHLW OKs Janssen’s HIV Combo Pill Prezcobix
November 24, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…